Afficher la couverture 'Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer | Cottu, P' en grand format
/5

0 avis

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Archive ouverte

Cottu, P | d'Hondt, V | Dureau, S | Lerebours, F | Desmoulins, I | Heudel, Pe | Duhoux, Fp | Levy, C | Mouret-Reynier, Ma | Dalenc, F | Frenel, Js | Jouannaud, C | Venat-Bouvet, L | Nguyen, S. | Ferrero, Jm | Canon, Jl | J, Grenier | Callens, C. | Gentien, D | Lemonnier, J | Vincent-Salomon, A | Delaloge, S

Edité par CCSD ; Elsevier -

International audience. Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC.

Consulter en ligne

Suggestions

Du même auteur

Hepatitis C virus infection and MALT-type ocular adnexal lymphoma

Archive ouverte | Arnaud, P. | CCSD

International audience

Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

Archive ouverte | Glasbey, James | CCSD

International audience. As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whet...

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study

Archive ouverte | Houillier, Caroline | CCSD

International audience. Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-prima...

Chargement des enrichissements...